School of Pharmacy, Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, People's Republic of China.
Med Res Rev. 2020 Mar;40(2):532-585. doi: 10.1002/med.21626. Epub 2019 Jul 30.
Telomere and telomerase play important roles in abnormal cell proliferation, metastasis, stem cell maintenance, and immortalization in various cancers. Therefore, designing of drugs targeting telomerase and telomere is of great significance. Over the past two decades, considerable knowledge regarding telomere and telomerase has been accumulated, which provides theoretical support for the design of therapeutic strategies such as telomere elongation. Therefore, the development of telomere-based therapies such as nucleoside analogs, non-nucleoside small molecules, antisense technology, ribozymes, and dominant negative human telomerase reverse transcriptase are being prioritized for eradicating a majority of tumors. While the benefits of telomere-based therapies are obvious, there is a need to address the limitations of various therapeutic strategies to improve the possibility of clinical applications. In this study, current knowledge of telomere and telomerase is discussed, and therapeutic strategies based on recent research are reviewed.
端粒和端粒酶在各种癌症中的异常细胞增殖、转移、干细胞维持和永生化中发挥着重要作用。因此，设计针对端粒酶和端粒的药物具有重要意义。在过去的二十年中，人们积累了大量关于端粒和端粒酶的知识，为端粒延长等治疗策略的设计提供了理论支持。因此，基于端粒的治疗方法，如核苷类似物、非核苷小分子、反义技术、核酶和显性负性人端粒酶逆转录酶的开发，正在优先用于消除大多数肿瘤。虽然基于端粒的治疗方法具有明显的优势，但需要解决各种治疗策略的局限性，以提高临床应用的可能性。在本研究中，讨论了端粒和端粒酶的现有知识，并综述了基于最新研究的治疗策略。
